• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES INTRACLUDE INTRA-AORTIC OCCLUSION DEVICE CLAMP, VASCULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES INTRACLUDE INTRA-AORTIC OCCLUSION DEVICE CLAMP, VASCULAR Back to Search Results
Model Number ICF100
Device Problems Difficult to Insert (1316); Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Embolism/Embolus (4438)
Event Date 10/18/2021
Event Type  Injury  
Event Description
Edwards received information that it was suspected that a small portion of the intima of the right femoral artery might have been loosened during femoral arterial cannulation with an er23 endoreturn cannula ((b)(4)). The fragment ended up in the ascending aorta, perhaps transported by the icf100 ((b)(4)) or wire introduced through the endoreturn cannula. It then migrated into the left main coronary artery. There was some calcification in the femoral artery that may have provided a platform for the separation of the intimal layer during cannulation. The patient expired later due to unknown reasons. As reported, the event was not due to edwards device malfunction. Additional information received: the surgical procedure was a robotic mitral valve repair/replacement. A sternotomy was performed with cabg x3. An aortotomy was done to recover and remove the section of the femoral artery intima that had been transported from the femoral artery into the ascending aorta either via an additional guidewire (non-edwards) and/or a catheter (including icf100). The femoral artery intima was discovered when the medical team saw the fragment on tee when looking at the ascending aorta. That was confirmed after the aortotomy and exploration of the left main coronary artery, when it was removed. The medical team believed the fragment came from the femoral artery because it was the only arterial access point (except the radial artery monitoring lines), and the caliber of the fragment was the same as the point of introduction of the femoral artery. Calcification in the femoral artery was identified on ct scan (visual and digital inspection) prior to the procedure. However, the impression was that it would not be problematic. There was some difficulty getting the guidewire supplied with the icf100 to advance smoothly. It was estimated that this difficulty was encountered at or just proximal to the aortic bifurcation. In regards to the occlusion of the left main, it was discovered upon exploration of the aortic root. The icf100 was introduced, positioned, but not used. The cause of death was due to an undisclosed clotting disorder that enabled clot to form in much of the vasculature in and around the heart. Anecdotally, the family disclosed a genetic abnormality after all the events. The patient had a history of coagulopathy.
 
Manufacturer Narrative
It was reported that a small portion of the intimal layer of the right femoral artery might have been detached during femoral arterial cannulation with an endoreturn cannula. Loose fragments in the vasculature have the potential to cause injury by embolization and causing infarction. In this case, the fragment was possibly pushed by a catheter (icf100) or guidewire up to the ascending aorta and ended up in the left main coronary artery. The investigation is still in progress; therefore, a conclusion has yet to be established. A supplemental report will be submitted accordingly upon investigation completion. The device history record (dhr) was not reviewed as the device lot number was not provided. The subject device is not available to be returned for evaluation as it was discarded. Edwards will continue to review and monitor all events. Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed. If new information becomes available, a supplemental report will be submitted.
 
Event Description
Edwards received information that it was suspected that a small portion of the intima of the right femoral artery might have been loosened during femoral arterial cannulation with an er23 endoreturn cannula (2021-18583-01). The fragment ended up in the ascending aorta, perhaps transported by the icf100 (2021-18583-02) or wire introduced through the endoreturn cannula. It then migrated into the left main coronary artery. There was some calcification in the femoral artery that may have provided a platform for the separation of the intimal layer during cannulation. The patient expired later due to unknown reasons. As reported, the event was not due to edwards device malfunction. Additional information received: the surgical procedure was a robotic mitral valve repair/replacement. A sternotomy was performed with cabg x3. An aortotomy was done to recover and remove the section of the femoral artery intima that had been transported from the femoral artery into the ascending aorta either via an additional guidewire (non-edwards) and/or a catheter (including icf100). The femoral artery intima was discovered when the medical team saw the fragment on tee when looking at the ascending aorta. That was confirmed after the aortotomy and exploration of the left main coronary artery, when it was removed. The medical team believed the fragment came from the femoral artery because it was the only arterial access point (except the radial artery monitoring lines), and the caliber of the fragment was the same as the point of introduction of the femoral artery. Calcification in the femoral artery was identified on ct scan (visual and digital inspection) prior to the procedure. However, the impression was that it would not be problematic. There was some difficulty getting the guidewire supplied with the icf100 to advance smoothly. It was estimated that this difficulty was encountered at or just proximal to the aortic bifurcation. In regards to the occlusion of the left main, it was discovered upon exploration of the aortic root. The icf100 was introduced, positioned, but not used. The cause of death was due to an undisclosed clotting disorder that enabled clot to form in much of the vasculature in and around the heart. Anecdotally, the family disclosed a genetic abnormality after all the events. The patient had a history of coagulopathy.
 
Manufacturer Narrative
It was reported that a small portion of the intimal layer of the right femoral artery might have been detached during femoral arterial cannulation with an endoreturn cannula. Loose fragments in the vasculature have the potential to cause injury by embolization and causing infarction. In this case, the fragment was possibly pushed by a catheter (icf100) or guidewire up to the ascending aorta and ended up in the left main coronary artery. The investigation is still in progress; therefore, a conclusion has yet to be established. A supplemental report will be submitted accordingly upon investigation completion. The device history record (dhr) was not reviewed as the device lot number was not provided. The subject device is not available to be returned for evaluation as it was discarded. Edwards will continue to review and monitor all events. Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed. If new information becomes available, a supplemental report will be submitted.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameINTRACLUDE INTRA-AORTIC OCCLUSION DEVICE
Type of DeviceCLAMP, VASCULAR
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer Contact
reginald santos
1 edwards way
irvine, CA 92614
9492502731
MDR Report Key12849198
MDR Text Key285160294
Report Number2015691-2021-06405
Device Sequence Number1
Product Code DXC
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K163693
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Consumer,Health Professional
Reporter Occupation
Type of Report Initial,Followup
Report Date 01/01/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/19/2021
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Model NumberICF100
Device Catalogue NumberICF100
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received01/01/2022
Was Device Evaluated by Manufacturer? No Answer Provided
Is This a Reprocessed and Reused Single-Use Device? No

Patient Treatment Data
Date Received: 11/19/2021 Patient Sequence Number: 1
-
-